Engflag

Arbitel-40

Quick links to important sections

Arbitel-40

Arbitel-40_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arbitel-40

Quick Facts

Property Description
Active ingredient Telmisartan
Form Oral Tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Common Use Management of high blood pressure
Origin Synthetic Compound

What Type of Medicine is Arbitel-40?

Arbitel-40 is a prescription-only medication whose active ingredient is Telmisartan. It is classified as an Angiotensin II Receptor Blocker (ARB), which is a therapeutic class of Antihypertensive Agents used to manage elevated blood pressure. Telmisartan is clinically recognized for possessing the longest terminal elimination half-life of all commercially available ARBs, approximately 24 hours, supporting its sustained, once-daily dosing regimen. This long duration of action ensures effective blood pressure control throughout the 24-hour cycle.

Composition and General Therapeutic Purpose

Telmisartan is a synthetic compound, specifically a non-peptide chemical entity derived from a Benzimidazole structure, distinguishing its molecular architecture within the ARB class. The medication is manufactured as a single-ingredient product formulated for oral administration as a tablet. The general purpose of Telmisartan is to lower and maintain blood pressure by performing a targeted receptor blockade, preventing natural substances that tighten blood vessels from taking effect. Telmisartan also possesses unique properties, including partial agonistic activity on the peroxisome proliferator-activated receptor-gamma (PPAR-γ), which may confer additional metabolic benefits beyond simple blood pressure reduction, enhancing its role in comprehensive cardiovascular risk management.

What side effects are possible with Arbitel-40?

Official Safety Profile and Adverse Reactions

The safety profile of Arbitel-40, containing telmisartan, is officially documented by regulatory authorities, classifying potential side effects by frequency and the body system affected. These classifications are based on clinical data and post-marketing reports, communicating the medicine's risk profile in a structured manner.

Adverse reactions are grouped into categories such as Uncommon and Rare. Uncommon reactions include effects such as upper respiratory and urinary tract infections, anemia, depression, hypotension (low blood pressure), cough, abdominal pain, diarrhea, rash, muscle spasms, and renal impairment. Rare reactions include more serious events like sepsis (including fatal outcome), anaphylactic reaction, angioedema (swelling beneath the skin or mucous membranes, also reported with fatal outcome), and hepatic function abnormal.

Serious Adverse Reactions and Constraints

Official labeling highlights the most critical safety concerns:

  • Fetal/Neonatal Risk: The medication is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal morbidity and mortality.
  • Organ Impairment: It is contraindicated in individuals with severe hepatic impairment (severe liver problems) or biliary obstructive disorders. For patients with mild to moderate hepatic impairment, a dose limitation of 40 mg daily applies.
  • Time-Related Pattern: Symptomatic hypotension may occur after the initial use, particularly in patients who are volume- or salt-depleted.

Regulatory documents also list an explicit contraindication for co-administration with aliskiren in patients with Type 2 Diabetes Mellitus.

Overdose and Emergency Response

Overdose Scope

Element Description (Based on Regulatory Labeling)
Documented overdose presentations Overexposure to Telmisartan is documented to cause exaggerated circulatory effects, including marked hypotension (low blood pressure) and heart rhythm disturbances, which may manifest as tachycardia (fast heartbeat) or bradycardia (slow heartbeat). Associated symptoms such as dizziness and fainting may also occur.
Physiological systems affected (as stated in label) The cardiovascular system is primarily affected (hemodynamic changes, rhythm disturbances). Renal function is also explicitly implicated.
Population-specific overdose notes (if applicable) Close monitoring for signs of hypotension, oliguria, and hyperkalemia is specifically required for infants with a history of in utero exposure.
Emergency-response statements (as written in official documents) Management involves symptomatic and supportive treatment. For symptomatic low blood pressure, official guidance includes placing the patient in the supine position and, if necessary, administering intravenous normal saline solution.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for a suspected overdose. Immediately call emergency services if the affected individual has collapsed, experienced a seizure, or cannot be awakened.

Overdose Classifications (High-Level)

Element Description (As Defined in Official Documents)
Severity classification (as defined in official documents) Severity is based on the potential for acute circulatory collapse and the risk of severe complications, particularly life-threatening hyperkalemia and acute worsening of renal function.
Overdose-context constraints (as defined in official documents) Limited information is available regarding overdose in humans, and no specific antidote is known.

Official Overdose Statements:

  • Overdose presents with pronounced hypotension and alterations in heart rate (tachycardia or bradycardia).
  • Severe outcomes include the risk of life-threatening hyperkalemia and acute worsening of renal function.
  • Immediate medical attention must be sought for suspected overdose or severe manifestations.
  • Management is limited to symptomatic and supportive treatment, including measures to restore volume and blood pressure.

Connection to the Overall Overdose Profile

Regulatory documents define the Arbitel-40 overdose profile by prioritizing the identification and management of acute circulatory changes, such as hypotension, and the risk of severe metabolic disturbances, such as hyperkalemia. Given that no specific antidote is known, regulatory bodies mandate symptomatic and supportive treatment while explicitly stating conditions under which immediate emergency medical help must be sought.

Therapeutic Uses of Arbitel-40

What Arbitel-40 treats: Main Uses and Benefits

Arbitel-40 is commonly used to help with conditions marked by increased physiological stress, related to systemic imbalance and cardiovascular contexts. This medication is primarily considered relevant for managing Essential Hypertension and for managing symptoms associated with acute or episodic changes in high-risk adult patients, including those with Type 2 Diabetes Mellitus, where symptoms linked to organ-specific functional stress are a concern.

A patient-oriented benefit is supportive relief, which may assist with managing symptoms associated with acute or episodic changes, helping to maintain a sense of stability when symptoms are more noticeable. It is relevant for easing symptoms linked to organ-specific functional stress, contributing to easing the overall symptom load.

Quick Fact: Symptom Support for Systemic Stress
Primary Goal Supports blood pressure management as part of addressing symptoms related to systemic imbalance.
Core Benefit Contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility for Arbitel-40 (Telmisartan): Official Restrictions

Eligibility for Arbitel-40 (Telmisartan) is strictly defined by regulatory authorities and depends on the patient's age, physiological status, and existing health conditions. The medicine is indicated for use in adults for managing high blood pressure and reducing cardiovascular risk. In geriatric patients (65 years and older), no initial dosage adjustment is typically required, though caution is advised.

Age-Related Status Eligibility Classification
Pediatric Population (under 18) Use is not established; safety and efficacy are unproven.

Absolute Contraindications (Must Not Use)

Arbitel-40 is formally contraindicated in several populations. These absolute prohibitions include:

  • Pregnancy (Second and Third Trimesters): Use is prohibited due to the risk of injury and death to the fetus.
  • Severe Hepatic Impairment: Contraindicated in patients with severe liver problems, cholestasis, or biliary obstructive disorders.
  • Hypersensitivity: Patients with known allergy to telmisartan or any component of the tablet.
  • Concomitant Use with Aliskiren: Prohibited in patients with diabetes mellitus or moderate-to-severe renal impairment who are also taking aliskiren-containing products.

Conditional Use and Restrictions

Patients with mild to moderate hepatic impairment must use the medicine with caution, often with a restricted maximum dose. Use is not recommended in the first trimester of pregnancy or for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Arbitel-40 (Telmisartan) is defined by its effects on drug transporters and its action on the Renin-Angiotensin System (RAS), as documented in official government regulatory documents.

Classification Interacting Agents / Conditions
Formal Contraindication Co-administration with Aliskiren is contraindicated in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m^2) [1.1, 2.1].
PK Exposure Modification Telmisartan acts as a P-glycoprotein (P-gp) inhibitor, which results in documented increases in Digoxin plasma concentrations. Increases in Lithium concentrations are also documented [2.2, 3.3].
Additive PD Effects Co-administration with ACE Inhibitors (Dual RAS Blockade) or Potassium-Sparing Diuretics (e.g., Spironolactone) is associated with an increased risk of hyperkalemia [2.1].
Antagonism / Renal Risk Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a documented loss of antihypertensive effect and increase the risk of renal impairment [1.1, 2.3].

The official regulatory documentation further notes that the use of Arbitel-40 is contraindicated in patients with Severe Hepatic Impairment or Biliary Obstructive Disorders due to expected reduced clearance. The combination with ACE Inhibitors or Lithium is generally not recommended due to documented risks [2.2, 2.3].

Mechanism of Action

How Arbitel-40 Works: Mechanism of Action

Arbitel-40's active substance, Telmisartan, works primarily by acting as a selective antagonist on the Angiotensin II Type 1 ( AT1) Receptor, the main mediator of the body's Renin-Angiotensin-Aldosterone System (RAAS). By blocking AT1, the drug prevents the powerful vasoconstrictor Angiotensin II from binding and triggering downstream effects like the contraction of vascular smooth muscle and the release of volume-retaining hormones such as Aldosterone. This sustained interference with the RAAS contributes to a modulation of systemic vascular resistance and extracellular fluid volume.

Beyond its primary vascular action, Telmisartan also functions as a partial agonist for the Peroxisome Proliferator-Activated Receptor-gamma ( PPAR-gamma) nuclear receptor. This secondary mechanism engages signaling pathways distinct from those governing vascular tone, influencing gene expression within metabolic systems. The partial activation of PPAR-gamma influences gene transcription of targets associated with metabolic regulation, including processes governing insulin signaling and lipid dynamics.

The drug’s mechanism is physiologically constrained in certain conditions where the AT1 receptor's normal function is critical for maintaining kidney pressure. Specifically, the blockade prevents Angiotensin II from constricting the efferent renal arteriole, which results in a decline in the Glomerular Filtration Rate (GFR) under conditions where the kidney depends on AT1-mediated efferent arteriolar constriction.

Dosage and Administration Information

How to Use Arbitel-40

The usage of Arbitel-40 (Telmisartan) is governed by established prescribing information, which defines the official methods and dosage rules for its administration.

Arbitel-40 is manufactured as a tablet intended for oral administration and is taken once daily. This once-daily schedule is designed to maintain consistent blood concentration over a 24-hour period, and the medication may be administered with or without food. To maintain this consistency, it is generally taken around the same time each day.

Official Dosing and Administration Rules

Feature Instruction Entity
Route of Administration Oral administration only.
Standard Daily Dosing Starting dose for hypertension is typically 40 mg once daily, with a usual maintenance range of 40 mg to 80 mg.
Maximum Dose The maximum prescribed daily dose is 80 mg.
Hepatic Impairment Constraint The dose must not exceed 40 mg once daily in patients with mild to moderate hepatic impairment.
Elderly Administration No initial dose adjustment is necessary for older adults.

Procedural and Handling Instructions

Telmisartan tablets are sensitive to moisture and must be protected from humidity. For this reason, the tablets should not be removed from the original blister pack until immediately before administration. If a dose is missed, it should be taken as soon as the oversight is noticed, unless it is almost time for the next scheduled dose; in that instance, the normal daily schedule should be resumed and two doses must not be taken at once.

The maximal blood pressure effect is typically attained after four weeks of continuous therapy, and dosage adjustments may be made after the initial 2 to 4 weeks if necessary.

Recent Clinical Evidence

Evidence for Managing Essential Hypertension (High Blood Pressure)

Research focusing on how Arbitel-40 was evaluated in adults with high blood pressure has primarily relied on short-term clinical trials, often lasting between six and twelve weeks, and subsequent meta-analyses. These controlled studies were conducted on adults diagnosed with mild-to-moderate essential hypertension. The research focused on populations and the specific physiological measurements taken over the defined time intervals, monitoring changes in both Systolic and Diastolic Blood Pressure (SBP/DBP).

While short-term research describes these measurable patterns, information on outcomes over many years remains limited when considering the duration of use. Long-term outcomes related to major cardiovascular events, such as heart attack or stroke, were not the primary focus of investigation for the mild-to-moderate hypertension population based on the design of these initial trials.

Evidence for Cardiovascular Risk Reduction in High-Risk Adults

Arbitel-40 was observed in large-scale, long-term research that examined the incidence of major cardiovascular events in specific high-risk populations. These studies primarily included adults aged 55 years and older who were identified as being at increased risk due to established vascular disease or Type 2 Diabetes Mellitus with related organ damage. The research monitored specific events (a key composite endpoint) that included cardiovascular death, non-fatal stroke, and non-fatal heart attack.

Findings describe patterns observed over follow-up periods that could extend beyond four years. However, data for certain groups, such as those interested in stroke prevention following an initial event, remain inconsistent and provide limited information. Furthermore, research exploring the agent in combination with another similar class of medication was associated with no measurable difference in cardiovascular or kidney outcomes compared to the single agents.

Gaps in Evidence and Areas of Uncertainty

Overall, certainty remains low regarding the full range of outcomes that may be observed outside the specific research scenarios studied. Data for other specialized populations, such as younger adults or certain individuals with comorbidities, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Arbitel-40 (FAQ)

Q: How quickly should I expect to see my blood pressure change after starting Arbitel-40?

A: According to official product information, Arbitel-40 is designed to provide sustained control over blood pressure. The maximum blood pressure lowering effect is generally achieved after four to eight weeks of continuous, regular treatment.

Q: What's the difference between Arbitel-40 and other common 'sartan' drugs?

A: Arbitel-40 belongs to the Angiotensin II Receptor Blocker (ARB) class, often referred to as 'sartans.' Regulatory information notes its relatively long duration of action and half-life, which supports its once-daily dosing.

Q: Is it normal to feel dizzy or lightheaded when first taking Arbitel-40?

A: Dizziness, feeling lightheaded, or fainting is commonly observed with this medicine. This may be a sign of low blood pressure (hypotension), especially when getting up quickly from a sitting or lying position.

Q: Can Arbitel-40 cause a persistent cough like some other blood pressure drugs?

A: Official safety data indicates that cough is reported as an uncommon side effect of Arbitel-40.

Q: What happens if I forget to take a dose of Arbitel-40?

A: Official regulatory guidance states that a missed dose may be taken as soon as the oversight is noticed. However, if it is almost time for the next scheduled dose, the normal schedule should be resumed, and it is stated that a patient should not take two doses at once.

Q: Is it safe to drink alcohol while I am on Arbitel-40?

A: Drinking alcohol may increase the blood pressure-lowering effects of Arbitel-40. This can increase the risk of symptoms such as dizziness, lightheadedness, and fainting.

Q: What common herbal supplements might interact with Arbitel-40?

A: Arbitel-40 can increase the risk of high potassium levels (hyperkalemia). Regulatory information indicates that the co-administration of potassium-containing salt substitutes or potassium supplements is typically avoided due to this risk.

Q: Is Arbitel-40 safe for elderly patients?

A: Official prescribing information states that no initial dosage adjustment is typically necessary for geriatric patients (65 years and older).

Q: Can younger adults be prescribed Arbitel-40 for high blood pressure?

A: Arbitel-40 is indicated for the treatment of high blood pressure in adults. Official regulatory sources state that safety and efficacy in pediatric patients (under 18) have not been established.

Q: Does Arbitel-40 affect heart rate or just blood pressure?

A: The primary mechanism of Arbitel-40 is focused on lowering blood pressure. However, changes in heart rhythm, such as a slow or fast heart rate, have been reported in postmarketing adverse reaction data.

Q: Why is Arbitel-40 often given as a combination pill with a diuretic?

A: Official drug information indicates that Arbitel-40 may be used in combination with a thiazide-type diuretic. This combination is noted to have an additive blood pressure lowering effect.

Q: Will I need to take Arbitel-40 for the rest of my life if my blood pressure is managed?

A: Arbitel-40 helps control high blood pressure, but it does not cure the condition. As high blood pressure is often a chronic condition, treatment usually requires continuous medication to maintain the desired blood pressure levels.

Q: Is there a generic version of Arbitel-40 available?

A: Yes, a generic version of the active ingredient, Telmisartan, is generally available.

Q: Why do people sometimes switch from an ACE inhibitor to Arbitel-40?

A: Arbitel-40 (an ARB) may be used as an alternative option, particularly for patients who experience a persistent dry cough, which can be a side effect of ACE inhibitor medications.

Q: Should I avoid certain activities while taking Arbitel-40 due to dizziness?

A: Official patient information states that Arbitel-40 may affect alertness. Activities such as driving or operating machinery should be approached with caution until a patient knows how the medicine affects them.

Q: What should I do if I experience a severe or unusual side effect from Arbitel-40?

A: Official regulatory documents indicate that severe or unusual side effects should be brought to the attention of a healthcare professional. Patients may also report suspected adverse reactions to their national regulatory authority.

Q: How is Arbitel-40 eliminated from the body?

A: The majority of Arbitel-40 is eliminated from the body unchanged. Pharmacokinetic data show that over 97% of the dose is excreted via the bile and feces.

Q: Are there any warning signs for liver issues related to Arbitel-40?

A: Official labeling states that the medicine is contraindicated in patients with severe liver problems or biliary obstructive disorders. Rare adverse reactions include abnormal hepatic function, which would involve monitoring by a healthcare professional.

Q: Is it common for doctors to adjust the Arbitel-40 dosage multiple times?

A: The initial dose is typically 40 mg once daily. Dosage adjustments may be made as needed, usually after the first four to eight weeks of starting treatment, to ensure optimal blood pressure control.

Q: Does Arbitel-40 treat the cause of high blood pressure or just the symptom?

A: Arbitel-40 works by blocking a hormone that causes blood vessels to tighten, which in turn lowers blood pressure. While it is highly effective at controlling blood pressure, it treats the symptom and does not cure the underlying condition.

Q: Does Arbitel-40 have any known psychiatric or mood-related side effects?

A: Yes, official safety data reports psychiatric adverse reactions in association with Arbitel-40. These include symptoms such as depression, nervousness, and anxiety.

Q: Are people with asthma or lung conditions able to take Arbitel-40?

A: Official adverse reaction data includes reports of respiratory effects such as asthma, rhinitis, and difficulty breathing (dyspnea). These conditions should be discussed with a healthcare professional.

Q: Why is my doctor checking my kidney function while I'm on Arbitel-40?

A: Periodic monitoring of blood levels of creatinine and potassium is recommended, particularly for patients with impaired kidney function. This is standard practice to manage the potential for mineral imbalance while taking this medication.

Q: Can Arbitel-40 cause issues with mineral balance in the body?

A: Regulatory information indicates that Arbitel-40 has the potential to cause high levels of potassium (hyperkalemia). Because of this potential, serum potassium and creatinine levels may be monitored in patients who are susceptible to these changes.

How should Arbitel-40 be stored and disposed of?

Storage and Disposal of Arbitel-40

To preserve the quality of Arbitel-40 (telmisartan), official regulatory documents require specific storage and handling conditions. The tablets must be stored at controlled room temperature (typically 20 C to 25 C). As the medicine is hygroscopic, it must be protected from moisture and light by remaining in its original container and sealed blister pack until immediately before use. Always store the product out of the sight and reach of children.

Disposal must follow official guidance. Unused or expired tablets should be managed through a community drug take-back program if available. Otherwise, the medicine may be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash. Do not flush the medicine down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Arbitel-40 found in:

A-Z Index: